Results 131 to 140 of about 138,518 (265)

Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria

Medicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a global health threat, with an estimated 282 million cases and 610,000 malaria‐associated deaths reported in 2024. Most mortality is due to infection by Plasmodium falciparum parasites, with the highest burden occurring in Sub‐Saharan Africa.
Wisam A. Dawood, Jacinta R. Macdonald, Christian Anzenhofer, Tina S. Skinner‐Adams, Robert C. Reid, Thomas Kurz, David P. Fairlie, Katherine T. Andrews   +7 more
wiley   +1 more source

Safety and efficacy of a novel glycoengineered recombinant vaccine candidate against Haemonchus contortus in sheep. [PDF]

NPJ Vaccines
Sajovitz-Grohmann F, Adduci I, Werling D, Wiedermann S, Wortha LN, Prole B, Zlöbl J, Elster J, Tichy A, Joachim A, Wittek T, Hinney B, Yan S, Lichtmannsperger K.   +13 more
europepmc   +1 more source

Plasmepsins as Antimalarial Drug Targets—Then, Now, and the Future

Medicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D‐like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential
Brad E. Sleebs
wiley   +1 more source

An adenovirus-vectored recombinant vaccine confers passive immunity protection from swine acute diarrhea syndrome coronavirus challenge in neonatal mice. [PDF]

Virol Sin
Zhang Y, Duan Y, Zhu X, Shi L, Zhang J, Mao W, Li L, Yuan C, Sun M, Zheng H, Wang Q.   +10 more
europepmc   +1 more source

The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy. [PDF]

Hum Vaccin Immunother, 2023
Lasagna A, Mele D, Bergami F, Alaimo D, Dauccia C, Alessio N, Comolli G, Pasi F, Muzzi A, Novelli V, Baldanti F, Pedrazzoli P, Cassaniti I.   +12 more
europepmc   +1 more source

Advances and challenges in experimental models for Epstein–Barr virus research

mLife, EarlyView.
Abstract Epstein–Barr virus (EBV), the first identified human oncovirus, is a ubiquitous γ‐herpesvirus etiologically linked to diverse malignancies, lymphoproliferative disorders, and autoimmune diseases. Experimental models are pivotal for unraveling the infection and pathogenesis mechanisms, life cycle regulation, as well as development and ...
Gulimire Wufuer, Jiabao Tang, Tingdong Li, Shengxiang Ge, Jun Zhang, Ningshao Xia   +5 more
wiley   +1 more source

A Multi-Epitope Recombinant Vaccine Candidate Against Bovine Alphaherpesvirus 1 and 5 Elicits Robust Immune Responses in Mice and Rabbits. [PDF]

Vaccines (Basel)
Barbosa AAS, Pereira SH, Laguardia-Nascimento M, Ferrari AB, Cox LJ, Rocha RP, Leocádio VAT, Ribeiro ÁL, Lourenço KL, Da Fonseca FG, Barbosa-Stancioli EF.   +10 more
europepmc   +1 more source

Intranasal administration with recombinant vaccine PRVXJ-delgE/gI/TK-S induces strong intestinal mucosal immune responses against PDCoV. [PDF]

BMC Vet Res, 2023
Huang B, Huang Y, Deng L, Xu T, Jian Z, Lai S, Ai Y, Zhu L, Xu Z.   +8 more
europepmc   +1 more source

Infection risk in rheumatoid arthritis patients treated with biologic and targeted therapies

Rheumatology &Autoimmunity, EarlyView.
In this context, infections associated with each biologic and targeted drug are summarized to inform the stratification of RA patients, including the characteristics of the susceptible patients and their concomitant therapy. We aim to provide a benefit‐risk analysis for clinical decision, and vital indications for the prevention of highly correlated ...
Lujing Wang, Jieshi Lin, Jie Qian
wiley   +1 more source

Biogenic silver nanoparticle as an adjuvant in an S1 subunit recombinant vaccine. [PDF]

Braz J Microbiol
de Freitas SB, Neto ACPS, Panagio LA, Collares TV, Seixas FK, Sousa FSS, Hartwig DD.   +6 more
europepmc   +1 more source